n Cardiovascular Journal of Africa - Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial : drug trends in cardiology




Results presented at the recent 2013 European Society of Cardiology congress in Amsterdam, The Netherlands, and published in the contribute to on-going questions concerning the safety of many diabetes treatments, particularly regarding the impact of their use on risk of cardiovascular death, heart attack or stroke. SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus) is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes mellitus (T2DM) patients at high risk for cardiovascular events.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error